HUENENBERG, Switzerland--(BUSINESS WIRE)--Alcon, Inc. (NYSE: ACL) announced today that it has submitted to the U.S. Food and Drug Administration (FDA) an amendment to its pending new drug application (NDA) for PATANASE® (olopatadine hydrochloride) nasal spray. The pending NDA is for the treatment of symptoms of seasonal allergic rhinitis in adults and adolescents twelve years of age and older. The amendment includes interim six-month data from an agreed-upon study previously requested by the FDA to support a modification of the formulation of PATANASE® nasal spray.
